Poor agreement of computerized calculators for mean amplitude of glycemic excursions.

abstract：:Although hypodermic needles rapidly deliver large doses of drugs such as insulin across the skin for systemic administration, the pain, local trauma, and difficulty to achieve sustained or complex delivery profiles has motivated development of novel alternative technologies. Microneedles, jet injectors, and thermal po...

journal_title：Diabetes technology & therapeutics

authors： Prausnitz MR

更新日期：2001-07-01 00:00:00

abstract：: Background: International consensus on the use of continuous glucose monitoring (CGM) recommends coefficient of variation (CV) as the metric of choice to express glycemic variability (GV) with a cutoff of 36% to define unstable diabetes. Even though, CV is associated with ...

journal_title：Diabetes technology & therapeutics

authors： Gómez AM,Henao DC,Imitola Madero A,Taboada LB,Cruz V,Robledo Gómez MA,Rondón M,Muñoz-Velandia O,García-Jaramillo M,León Vargas FM

更新日期：2019-08-01 00:00:00

abstract：: Background: The financial strain of type 1 diabetes on the United States health care system, patients, and employers underscores the importance of developing novel treatments for the disease. This study estimated the lifetime economic burden attributable to type 1 diabetes...

journal_title：Diabetes technology & therapeutics

authors： Sussman M,Benner J,Haller MJ,Rewers M,Griffiths R

更新日期：2020-02-01 00:00:00

abstract：:Diabetic nephropathy is one of the major causes of end-stage renal disease and is often associated with other macrovascular complications such as ischemic heart disease and peripheral vascular disease. Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (AIIR) have both been shown to ...

journal_title：Diabetes technology & therapeutics

authors： Boner G,Cao Z,Cooper ME

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Lipohypertrophy (LH) is a complication of insulin therapy. We assessed LH prevalence, risk factors, insulin usage, and clinical and health economic effects in China. METHODS:In four cities, 401 adult patients injecting insulin ≥1 year were surveyed for diabetes/insulin injection history and practices, pen n...

journal_title：Diabetes technology & therapeutics

authors： Ji L,Sun Z,Li Q,Qin G,Wei Z,Liu J,Chandran AB,Hirsch LJ

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:The purpose of this study is to test the agreement between energy expenditure estimate of the SenseWear(®) Armband Pro3 (SWA) (BodyMedia, Pittsburgh, PA) and the Omron HJ-720 (Omron Healthcare, Kyoto, Japan) step counter with indirect calorimetry (IC) as a gold standard in older individuals with type 1 and t...

journal_title：Diabetes technology & therapeutics

authors： Machač S,Procházka M,Radvanský J,Slabý K

更新日期：2013-05-01 00:00:00

abstract：:Clustering of diseases has been appreciated by health insurers and epidemiologists for some time. Co-morbidity suggests shared pathways of disease. It is by now well agreed that common diseases have a strong genetic component. Here we present evidence that the angiotensin I-converting enzyme (ACE) deletion/deletion (D...

journal_title：Diabetes technology & therapeutics

authors： Moskowitz DW

更新日期：2002-01-01 00:00:00

abstract：:The microdialysis technique allows extraction of substances (e.g., glucose) from fluids in the human body for quantitative measurements ex vivo. The microdialysis catheter can be inserted in many different tissues; for continuous glucose monitoring it is most often implanted in the subcutaneous fat tissue in the abdom...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L,Glucose Monitoring Study Group.

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Programmable and fixed auditory and/or vibratory threshold alerts are essential features of real-time continuous glucose monitoring (rtCGM) systems that provide users time to intervene before the onset of clinical hypoglycemia or hyperglycemia. A sixth-generation rtCGM system from Dexcom, Inc. (G6) includes ...

journal_title：Diabetes technology & therapeutics

authors： Puhr S,Derdzinski M,Welsh JB,Parker AS,Walker T,Price DA

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:The aim of this study was to elucidate the characteristics of accuracy of subcutaneous continuous glucose monitoring (SCGM) in the perioperative period for neurosurgical and cardiac surgery patients. METHODS:Forty-five subjects, including healthy volunteers (n = 15), neurosurgical patients (n = 15), and car...

journal_title：Diabetes technology & therapeutics

authors： Sugiyama Y,Wakabayashi R,Urasawa M,Maruyama Y,Shimizu S,Kawamata M

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) provides glucose trend information that can be used to guide treatment and motivate patients with diabetes. Currently, the evidence on effectiveness of CGM in patients with type 2 diabetes is debatable. We aim to provide a systematic review and meta-analysis to synthesize ...

journal_title：Diabetes technology & therapeutics

authors： Park C,Le QA

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:The management of hyperglycemia in the intensive care unit has been a controversial topic for more than a decade, with target ranges varying from 80-110 mg/dL to <200 mg/dL. Multiple insulin infusion protocols exist, including several computerized protocols, which have attempted to achieve these targets. Imp...

journal_title：Diabetes technology & therapeutics

authors： Marvin MR,Inzucchi SE,Besterman BJ

更新日期：2016-08-01 00:00:00

abstract：:This study was designed to determine plasma glucose and insulin levels after administration of three escalating doses of the oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in fasting, insulin-deprived adult patients with type 1 diabetes. The study was also designed to assess the safety of the product. Sixte...

journal_title：Diabetes technology & therapeutics

authors： Clement S,Still JG,Kosutic G,McAllister RG

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring is a useful tool for the achievement of improved glucose control in patients with diabetes. We tested the ability of a novel noninvasive continuous glucose monitor to track glucose excursions. METHODS:The novel noninvasive Aprise sensor (Glucon Inc., Boulder, CO) utilizes the p...

journal_title：Diabetes technology & therapeutics

authors： Weiss R,Yegorchikov Y,Shusterman A,Raz I

更新日期：2007-02-01 00:00:00

abstract：:Self-monitoring of blood glucose was described as one of the most important advancements in diabetes management since the invention of insulin in 1920. Recent advances in glucose sensor technology for measuring interstitial glucose concentrations have challenged the dominance of glucose meters in diabetes management, ...

journal_title：Diabetes technology & therapeutics

authors： Cengiz E,Tamborlane WV

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:For patients with type 1 diabetes mellitus, a bihormonal artificial endocrine pancreas system utilizing glucagon and insulin has been found to stabilize glycemic control. However, commercially available formulations of glucagon cannot currently be used in such systems because of physical instability characte...

journal_title：Diabetes technology & therapeutics

authors： Caputo N,Jackson MA,Castle JR,El Youssef J,Bakhtiani PA,Bergstrom CP,Carroll JM,Breen ME,Leonard GL,David LL,Roberts CT Jr,Ward WK

更新日期：2014-11-01 00:00:00

abstract：BACKGROUND:Proper healing of ulcers and wounds on the feet of diabetes patients is important in order to prevent amputation. If the wound area reduction during the first 4 weeks of the treatment is not 40% or more, reevaluation of the treatment is necessary. The wound area evaluation is not complicated when the patient...

journal_title：Diabetes technology & therapeutics

authors： Foltynski P,Ladyzynski P,Migalska-Musial K,Sabalinska S,Ciechanowska A,Wojcicki J

更新日期：2011-08-01 00:00:00

abstract：OBJECTIVE:To assess whether snacking could be used with closed-loop (CL) insulin delivery to avoid exercise-induced reductions in plasma glucose (PG), as well as elevations in PG at the end of exercise. RESEARCH DESIGN AND METHODS:Twelve type 1 diabetes (T1D) subjects (age 13-36 years, duration 10.7 ± 8.4 years, A1c 7...

journal_title：Diabetes technology & therapeutics

authors： Patel NS,Van Name MA,Cengiz E,Carria LR,Tichy EM,Weyman K,Weinzimer SA,Tamborlane WV,Sherr JL

更新日期：2016-12-01 00:00:00

abstract：AIM:This study explored the role of glycemic control on cardiac autonomic function, measured by heart rate variability (HRV), in youth with type 1 diabetes. PATIENTS AND METHODS:A retrospective cohort of 345 youth with type 1 diabetes (mean age, 18.5 years; duration, 10 years) participating in the SEARCH for Diabetes ...

journal_title：Diabetes technology & therapeutics

authors： Jaiswal M,Fingerlin TE,Urbina EM,Wadwa RP,Talton JW,D'Agostino RB Jr,Hamman RF,Daniels SR,Marcovina SM,Dolan LM,Dabelea D

更新日期：2013-12-01 00:00:00

abstract：: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

journal_title：Diabetes technology & therapeutics

authors： Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

更新日期：2020-03-01 00:00:00

abstract：:Rates of diabetes are increasing worldwide and there is not a sufficient clinical workforce to care for these patients. Diabetes-related apps are a feasible way to provide diabetes education to large numbers of people with diabetes but attrition rates are high. Apps enhanced by virtual coaching may be a way to circumn...

journal_title：Diabetes technology & therapeutics

authors： Ramchandani N

更新日期：2019-06-01 00:00:00

abstract：BACKGROUND:Diabetic foot ulcer area is a basic parameter used for monitoring the wound healing and effectiveness of the treatment applied. TeleDiaFoS (developed earlier in collaboration with the Department and Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland) is one of jus...

journal_title：Diabetes technology & therapeutics

authors： Ladyzynski P,Foltynski P,Molik M,Tarwacka J,Migalska-Musial K,Mlynarczuk M,Wojcicki JM,Krzymien J,Karnafel W

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:This exploratory study examined the pharmacokinetics and pharmacodynamics of a Bentley Pharmaceuticals, Inc. (North Hampton, NH) proprietary insulin formulation utilizing CPE-215 technology designed for intranasal administration. METHODS:Eight fasting healthy volunteers (four men, four women; body mass inde...

journal_title：Diabetes technology & therapeutics

authors： Leary AC,Stote RM,Breedt HJ,O'Brien J,Buckley B

更新日期：2005-02-01 00:00:00

abstract：:The increasing prevalence of type 1 and type 2 diabetes mellitus combined with advancement in early detection of cardiovascular disease (CVD) has placed CVD as a significant concern for preventative pediatric medicine. The public health burden of type 2 diabetes is predicted to parallel increasing obesity in children ...

journal_title：Diabetes technology & therapeutics

authors： Truong UT,Maahs DM,Daniels SR

更新日期：2012-06-01 00:00:00

abstract：BACKGROUND:Patients with diabetes do daily self-monitoring of blood glucose (SMBG). For such patients, we devised an engine that predicts not only the expected blood glucose level at the next meal but also the pending risks of hypoglycemia. The purpose of this study was to validate the predictions and provide evidence ...

journal_title：Diabetes technology & therapeutics

authors： Albisser AM,Sakkal S,Wright C

更新日期：2005-06-01 00:00:00

abstract：BACKGROUND:We evaluated the impact of a 2-year chat line involving adolescents with type 1 diabetes regarding quality of life and metabolic control. METHODS:We enrolled 193 children, 10-18 years of age (mean ± SD, 13.6 ± 2.7 years), with type 1 diabetes for 1.2-6 years (3.6 ± 2.4 years), body mass index of 23.2 ± 4.1 ...

journal_title：Diabetes technology & therapeutics

authors： Iafusco D,Galderisi A,Nocerino I,Cocca A,Zuccotti G,Prisco F,Scaramuzza A

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：:The transplantation of microencapsulated islets may allow reversal of hyperglycemia in the absence of immunosuppression. Poly-L-lysine (PLL) on capsules may potentiate the fibrotic reaction against implanted capsules. The aims of this study were to investigate how the biocompatibility of such capsules affects their fu...

journal_title：Diabetes technology & therapeutics

authors： King A,Lau J,Nordin A,Sandler S,Andersson A

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12. METHODS:On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and und...

journal_title：Diabetes technology & therapeutics

authors： Bailey TS,Zisser HC,Garg SK

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:This study was designed to assess the accuracy, reliability, and contribution to clinical decision-making of two commercially available continuous glucose monitoring (CGM) devices using a novel analytical approach. STUDY DESIGN:Eleven individuals with type 1 diabetes and five with type 2 diabetes wore a Gua...

journal_title：Diabetes technology & therapeutics

authors： Mazze RS,Strock E,Borgman S,Wesley D,Stout P,Racchini J

更新日期：2009-01-01 00:00:00